Assessment of parameters of the acid-base state among patients with meningiomas and gliomas in the postoperative period

SUMMARY. In the adult population, meningiomas are observed in 18–34 % of all intracranial neoplasms, confidently taking second place among brain tumors and second only to gliomas. With meningiomas, the incidence is ~ 4–6 people per 100 thousand population. Gliomas are the most common primary brain tumors: they account for up to 81 % of all malignant neoplasms of the central nervous system.
PURPOSE OF THE STUDY: to evaluate the parameters of the acid-base state in patients with meningiomas and gliomas in the early postoperative period and to evaluate the metabolism of tumors.
MATERIALS AND METHODS: the data of analyses of the acid-base state indicators of patients with gliomas and meningiomas being treated at the neurosurgical department No. 4 of the Polenov Neurosurgical Research Institute, who were divided into two groups: 20 patients with high grade tumors (mainly Grade III and IV gliomas, 10 men and 10 women) and 19 with low grade (mostly Grade I meningiomas, 9 males and 10 females). The study of the acid-base state indicators was carried out in the postoperative period, for comparison, the nonparametric mann-Whitney criterion was used.
RESULTS. Among patients with high grade tumors, there is an increased average ph value and a reduced average pCO2 value, which indicates gas acidosis, and not the initially expected metabolic alkalosis. Among patients with low grade tumors, deviations from the normal values of the acid-base state were not detected. mann-Whitney statistical analysis shows a high level of reliability in terms of ph and pCO2. For the remaining indicators, there are no deviations from normal values and the confidence level is low.
CONCLUSION. During the analysis of the indicators of the acid-base state of patients with gliomas, it was found that the values obtained indicate gas alkalosis, and not the initially expected metabolic acidosis, presumably in connection with the provision of resuscitation benefits. In conclusion, there is no significant effect of tumors on systemic metabolomics, which makes it possible not to take it into account when conducting further studies of local tumor metabolism.

1. Kadasheva A . B., Kozlov A . V ., Shifrin M . A ., et al. Radiation-induced meningiomas: analysis of 33 cases. Zhurnal Voprosy Neirokhirurgii Imeni N. N. Burdenko. 2020;84(3):53–60.(In R uss.). https://www.mediasphera.ru/issues/zhurnal-voprosy-nejrokhirurgii-imeni-n-n-burdenko/2020/3/1004288172020031053

2. Morrison V . V ., Chesnokova N. P ., Bizenkova M . N. A cid-base state. Typical violations of the acid-base state (lecture № 2). International Journal of Applied and Fundamental Research. 2015;3(2):273–278. (In R uss.).] ED N: TMJ TGJ

3. Tepaev R . F., Lastovka V . A ., Pytal A . V ., et al. Metabolic Acidosis: Diagnostics and Treatment. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2016;13(4):384–389. (In R uss.).] https://cyberleninka.ru/article/n/metabolicheskiy-atsidoz-diagnostika-ilechenie/viewer

4. Yakovlenko Y . G . G lioblastoma: the current state of the problem. Medical Herald of the South of Russia. 2019;10(4):28–35. (In Russ.).] https://www.medicalherald.ru/jour/article/view/970/534

5. A. Finch, G. Solomou, V. W ykes, U. P ohl, C. Bardella, C. W atts. Advances in Research of Adult Gliomas. International Journal of Molecular Sciences. 2021;22(2):924. DOI:10.3390/ijms22020924. https://www.mdpi.com/1422–0067/22/2/924

6. A. M aus, G. J . P eters. Glutamate and α-ketoglutarate: key players in glioma metabolism. Amino Acids. 2017;49:21–32. https://doi.org/10.1007/s00726‑016‑2342‑9. https://www.ncbi.nlm.nih.gov/pmc/articles/PM C 6828266/

7. A. Sharma, J. J . G raber. Overview of prognostic factors in adult gliomas. Annals of Palliative Medicine. 2021;10(1):863–874. https://doi.org/10.21037/apm‑20–640. https://apm.amegroups.com/article/view/48935/html

8. C. Apra, M. P eyre, M. Kalamarides. Current treatment options for meningioma. Expert Review of Neurotherapeutics. 2018;18(3):241–249. https://doi.org/10.1080/14737175.2018.1429920. https://www.tandfonline.com/doi/abs/10.1080/14737175.2018.1429920?journalCode=iern20

9. J. R . M cFaline-Figueroa, T. J . Kaley, I. F. D unn, W. L . Bi. Biology and Treatment of Meningiomas: A Reappraisal. Hematology/Oncology Clinics of North America. 2022;36(1):133–146. https://doi.org/10.1016/j.hoc.2021.09.003. https://www.sciencedirect.com/science/article/abs/pii/S 0889858821001180?via%3Dihub

10. J. G . Nicholson, H. A . Fine. Diffuse Glioma Heterogeneity and Its Therapeutic Implications. Cancer Discovery. 2021;11(3):575–590. https://doi.org/10.1158/2159–8290. https://www.tandfonline.com/doi/abs/10.1080/14737175.2018.1429920?journalCode=iern20

11. K. Kerr, K. Q ualmann, Y. E squenazi, J. Hagan, D. H. Kim. Familial Syndromes Involving Meningiomas Provide Mechanistic Insight Into Sporadic Disease. Neurosurgery. 2018;83(6):1107–1118. https://doi.org/10.1093/neuros/nyy121. https://www.ncbi.nlm.nih.gov/pmc/articles/PM C 6235681/

12. Lee Y . S. Molecular characteristics of meningiomas. Journal of Pathology and Translational Medicine. 2020;54(1):45–63. https://doi.org/10.4132/jptm.2019.11.05.

13. M. W eller, M. van den Bent, M. P reusser, E. L e Rhun, J. C. Tonn, G. M inniti, M. Bendszus, C. Balana, O. Chinot, L. D irven, P. French, M. E . Hegi, A. S. J akola, M. P latten, P. R oth, R. R udà, S. Short, M. Smits, M.J.B. Taphoorn, A. von Deimling, M. W estphal, R. Soffietti, G. R eifenberger, W. W ick. EA NO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nature Reviews Clinical Oncology. 2021;18(3):170–186. https://doi.org/10.1038/s41571–020–00447-z. https://pubmed.ncbi.nlm.nih.gov/33293629/

14. O. Romanidou, V. Kotoula, G. Fountzilas. Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas. Cancer Genomics Proteomics. 2018;15(5):421–436. https://doi.org/10.21873/cgp.20101. https://www.ncbi.nlm.nih.gov/pmc/articles/PM C 6199574/

15. P. W esseling, M. van den Bent, A. P erry. Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathologica. 2015;129:809–827. https://doi.org/10.1007/s00401‑015‑1424‑1. https://www.ncbi.nlm.nih.gov/pmc/articles/ PM C 4436696/

16. P. K. Brastianos, E. G alanis, N. Butowski, J. W . Chan, I. F. D unn, R. G oldbrunner, C. Herold-Mende, F. M . Ippen, C. M awrin, M. W . M c Dermott, A. Sloan, J. Snyder, G. Tabatabai, M. Tatagiba, J. C. Tonn, P. Y . W en, K. A ldape, F. Nassiri, G. Zadeh, M. D . J enkinson, D. R . R aleigh; International Consortium on Meningiomas. Advances in multidisciplinary therapy for meningiomas. Neuro-Oncology. 2019;21(1): i18-i31. https://doi.org/10.1093/neuonc/noy136. https://www.ncbi.nlm.nih.gov/pmc/articles/PM C 6347080/

17. R. A . Buerki, C. M . Horbinski, T. Kruser, P. M . Horowitz, C. D . J ames, R. V . L ukas. An overview of meningiomas. Future Oncology. 2018;14(21):2161–2177. https://doi.org/10.2217/fon‑2018–0006. https://www.ncbi.nlm.nih.gov/pmc/articles/PM C 6123887/

18. S. Suppiah, F. Nassiri, W. L . Bi, I. F. D unn, C. O . Hanemann, C. M . Horbinski, R. Hashizume, C. D . J ames, C. M awrin, H. Noushmehr, A. P erry, F. Sahm, A. Sloan, A. V on Deimling, P. Y . W en, K. A ldape, G. Zadeh; International Consortium on Meningiomas. Molecular and translational advances in meningiomas. Neuro Oncol. 2019;21: i4-i17. https://doi.org/10.1093/neuonc/noy178. https://www.ncbi.nlm.nih.gov/pmc/articles/PM C 6347079/

19. Sue Han, Yang Liu, Cai S. J ., et al. IDH mutation in glioma: molecular mechanisms and potential targets. British Journal of Cancer. 2020;122: 1580–1589. https://doi.org/10.1038/s41416–020–0814-x. https://www.ncbi.nlm.nih.gov/pmc/articles/PM C 7250901/

20. T. G . Krieger, S. M . Tirier, J. P ark, K. J echow, T. E isemann, H. P eterziel, P. A ngel, R. E ils, C. Conrad. Modeling glioblastoma invasion using human brain organoids and single-cell transcriptomics, Neuro-Oncology, 2020;22(8):1138–1149. https://doi.org/10.1093/neuonc/noaa091. https://www.ncbi.nlm.nih.gov/pmc/articles/PM C 7594554/

21. Р. Śledzińska, M. G . Bebyn, J. Furtak, J. Kowalewski, M. A . L ewandowska. Prognostic and Predictive Biomarkers in Gliomas. International Journal of Molecular Science. 2021;22(19):10373. https://doi.org/10.3390/ijms221910373. https://www.ncbi.nlm.nih.gov/pmc/articles/PM C 8508830/

22. R. Soffietti, D. N. L ouis, A. P erry, P. W esseling, D. J . Brat, I. A . Cree, D. Figarella-Branger, C. Hawkins, H. K. Ng, S. M . P fister, G. R eifenberger, A. von Deimling, D. W . E llison. The 2021 W HO Classification of Tumors of the Central Nervous System: a summary, Neuro-Oncology, Volume 23, Issue 8, August 2021, Pages 1231–1251, https://doi.org/10.1093/neuonc/noab106. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC 8328013/

23. Badu S. K., Medynik I. A. Factors affecting the transformation of anaplastic glioma to glioblastoma. Rossiiskii neirokhirurgicheskii zhurnal imeni professora A. L . P olenova. 2021;13(2–3):14–17. (In Russ.).

24. Trofimov V . E ., Ulitin A . Y ., Matsko M . V ., et al. Multiple malignant cerebral gliomas. clinical-pathomorphological features and results of complex treatment. Rossiiskii neirokhirurgicheskii zhurnal imeni professora A. L . Polenova. 2022;14(4):89–97. (In Russ.).]